MeadowStream wrote:You are a really laugh a minute!
You know as well as the rest of us here that you are merely trying to spread fear, uncertainty and dread around Tysabri. It isn't working.
You also know, or should know (Lauren posted the AER above,) that the consumer (in the case of the Belgian patient) cited Remicade as primary cause of death.
Thanks for the invite to Ontario. Would you like to come down to Mexico City to show me your emails? Will expect you this weekend.
MeadowStream wrote:We aren't talking about prozac or paxil Harry. We are talking about Tysabri. The AER database, the one maintained by law by the FDA, has the consumer-filed report and that is not up for debate: remicade was called out as the culprit. No company filed that report, the consumer did. Not the doctor, but the consumer.
Regardless of your claims here, I do not believe anything you say regarding the Crohn's patient: you are vehemently anti-Tysabri to the point of mania. There are well over 22,000 patients on Tysabri with no deaths and no PML. In fact, by mid-year a PML case would only bring Tysabri patients up to the national average. But it won't happen because TOUCH is preventing immune compromised patients from receiving Tysabri and because MS patients are naturally immunized against PML (unlike the 2 non-MS patients who were improperly diagnosed and dosed with Tysabri during trials.)
The NEJM by the way also wrote that it is safer to take Tysabri than not to take Tysabri. Interesting, huh?
Users browsing this forum: No registered users